| Characteristics | Cohort | |||
| N (%) | Before COVID-19 (%) | During COVID-19 (%) | p-value | |
| Patient status |
|
|
| 0.033 |
| · New | 206 (96.3) | 108 (99.1) | 98 (93.3) |
|
| · Relapse | 8 (3.7) | 1 (0.9) | 7 (6.7) |
|
| Patient outcome |
|
|
| 0.171 |
| · Interruption of treatment | 9 (4.2) | 7 (6.4) | 2 (1.9) |
|
| · On treatment | 205 (95.8) | 102 (93.6) | 103 (98.1) |
|
| Type of tuberculosis |
|
|
| 0.539 |
| · Extra-pulmonary | 31 (15.1) | 17 (16.7) | 14 (13.6) |
|
| · Pulmonary | 174 (84.9) | 85 (83.3) | 89 (86.4) |
|
| TB treatment protocol |
|
|
| 1.0 |
| · RH | 4 (2.3) | 2 (2.3) | 2 (2.2) |
|
| · RHEZ | 171 (97.7) | 84 (97.7) | 87 (97.8) |
|
| Knowledge of treatment duration |
|
|
| 0.769 |
| · Yes | 194 (94.6) | 97 (95.1) | 97 (94.2) |
|
| · No | 11 (5.4) | 5 (4.9) | 6 (5.8) |
|
| Side effect |
|
|
| 0.924 |
| · Yes | 134 (65.4) | 67 (65.7) | 67 (65.0) |
|
| · No | 71 (34.6) | 35 (34.3) | 36 (35.0) |
|